{"slug":"retatrutide-chemo-neuropathy","verification":{"valid":true,"entries":4,"head":"f46e7ff141247166dfadb85f52b95aa05dc25a029bc85b486fc5c91540d1fcd9"},"count":4,"sources":[{"id":"s9","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11674975/","title":"Chemotherapy-Induced Peripheral Neuropathy: Assessment ...","quote":"Seretny et al. (2014) conducted a large systematic review with 4,179 patients and found that the prevalence of CIPN after chemotherapy was 68% at one month, 60% at three months, and 30% at six months.","summary":"Systematic review on CIPN prevalence and persistence.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:28.313Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"05a630838dba6977085a404a90a897530183d0834d7981e78f983ce958cce286"},{"id":"s2","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 human trial results on retatrutide weight loss.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:28.313Z","link_status":"http_403","quote_status":"unverified","prev":"05a630838dba6977085a404a90a897530183d0834d7981e78f983ce958cce286","hash":"9709de18985082872356613666a60434cb92314cc06f2d6d0c4d260a36ec6e8b"},{"id":"s3","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss...","quote":"In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks...","summary":"Phase 3 trial summary from manufacturer.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:28.313Z","link_status":"ok","quote_status":"unverified","prev":"9709de18985082872356613666a60434cb92314cc06f2d6d0c4d260a36ec6e8b","hash":"4cd73093960c9184759edb345ec02110fb6b75c829578d8934891c80798b36f1"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral ...","quote":"For the prevention setting, our meta-analysis shows that pregabalin did not significantly improve average pain (standardised mean difference (SMD) -0.14, 95% CI -0.51 to 0.23...","summary":"Meta-analysis on gabapentinoids in CIPN.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:28.313Z","link_status":"ok","quote_status":"unverified","prev":"4cd73093960c9184759edb345ec02110fb6b75c829578d8934891c80798b36f1","hash":"f46e7ff141247166dfadb85f52b95aa05dc25a029bc85b486fc5c91540d1fcd9"}]}